Novozymes (BMV:NSIS N) - Stock Price, News & Analysis

NSIS N Stock Overview

Produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally.

About the company

NSIS N fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	3/6
Financial Health	4/6
Dividends	3/6

Rewards

Earnings are forecast to grow 19.52% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Has a high level of debt

Novonesis A/S Competitors

Grupo México. de

BMV:GMEXICO B

Mex$877.7b

CEMEX. de

BMV:CEMEX CPO

Mex$182.6b

Industrias Peñoles. de

BMV:PE&OLES *

Mex$116.2b

PPG Industries

NYSE:PPG

US$31.4b

Price History & Performance

Summary of all time highs, changes and price drops for Novozymes
Historical stock prices
Current Share Price	DKK 911.11
52 Week High	DKK 938.65
52 Week Low	DKK 730.70
Beta	0.48
11 Month Change	0%
3 Month Change	n/a
1 Year Change	0.47%
33 Year Change	-31.10%
5 Year Change	0.96%
Change since IPO	15.79%

Recent updates

Shareholder Returns

	NSIS N	MX Chemicals	MX Market
7D	0%	2.0%	1.1%
1Y	0.5%	-22.2%	3.8%

Return vs Industry: NSIS N exceeded the MX Chemicals industry which returned -8.5% over the past year.

Return vs Market: NSIS N underperformed the MX Market which returned 4.2% over the past year.

Price Volatility

Is NSIS N's price volatile compared to industry and market?
NSIS N volatility
NSIS N Average Weekly Movement	n/a
Chemicals Industry Average Movement	3.8%
Market Average Movement	4.1%
10% most volatile stocks in MX Market	6.2%
10% least volatile stocks in MX Market	2.7%

Stable Share Price: NSIS N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NSIS N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1925	6,577	Ester Baiget	www.novonesis.com

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Novonesis A/S Fundamentals Summary

How do Novozymes's earnings and revenue compare to its market cap?
NSIS N fundamental statistics
Market cap	Mex$419.73b
Earnings (TTM)	Mex$7.22b
Revenue (TTM)	Mex$42.74b

58.1x

P/E Ratio

9.8x

P/S Ratio

Is NSIS N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NSIS N income statement (TTM)
Revenue	DKK 17.90b
Cost of Revenue	DKK 8.18b
Gross Profit	DKK 9.72b
Other Expenses	DKK 6.70b
Earnings	DKK 3.02b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 03, 2024

Earnings per share (EPS)	6.51
Gross Margin	54.32%
Net Profit Margin	16.89%
Debt/Equity Ratio	51.6%

How did NSIS N perform over the long term?

See historical performance and comparison

Dividends

1.7%

Current Dividend Yield

88%

Payout Ratio

NSIS N Stock Overview

Rewards

Risk Analysis

Novonesis A/S Competitors

BMV:GMEXICO B

Mex$877.7b

BMV:CEMEX CPO

Mex$182.6b

BMV:PE&OLES *

Mex$116.2b

NYSE:PPG

US$31.4b

Price History & Performance

Recent News & Updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Less than half of directors are independent

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Revenue Guidance for 2022

Less than half of directors are independent

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Full Year 2021